Fluicell AB (publ) (STO:FLUI)
Sweden
· Delayed Price · Currency is SEK 10.80
-0.40 (-3.57%)
At close: Mar 6, 2026
Fluicell AB Revenue
In the year 2025, Fluicell AB had annual revenue of 15.22M SEK with 184.54% growth. Fluicell AB had revenue of 6.02M in the quarter ending December 31, 2025, with 50.37% growth.
Revenue
15.22M
Revenue Growth
+184.54%
P/S Ratio
0.97
Revenue / Employee
1.38M
Employees
11
Market Cap
14.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.22M | 9.87M | 184.54% |
| Dec 31, 2024 | 5.35M | 2.01M | 60.25% |
| Dec 31, 2023 | 3.34M | 87.00K | 2.68% |
| Dec 31, 2022 | 3.25M | 649.00K | 24.94% |
| Dec 31, 2021 | 2.60M | -2.03M | -43.86% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novakand Pharma AB | 14.00K |
| NanoEcho AB | 487.00K |
| Aptahem AB | 2.59M |
| Stayble Therapeutics AB | 47.00K |
| ExpreS2ion Biotech Holding AB | 10.85M |
| Nanologica AB | 21.13M |
| 2cureX AB | 1.98M |
| AcouSort AB | 10.43M |